Mei Y. Koh, PhD


  • English

Academic Information

  • Departments: Pharmacology and Toxicology - Assistant Professor

Selected Publications

Journal Article

  1. Maruggi M, Layng FI, Lemos R Jr, Garcia G, James BP, Sevilla M, Soldevilla F, Baaten BJ, de Jong PR, Koh MY, Powis G (2019). Absence of HIF1A Leads to Glycogen Accumulation and an Inflammatory Response That Enables Pancreatic Tumor Growth. Cancer Res, 79(22), 5839-5848.
  2. Green YS, Sargis T, Reichert EC, Rudasi E, Fuja D, Jonasch E, Koh MY (2019). Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia. Mol Cancer Res, 17(5), 1220-1232.
  3. Grandjean G, de Jong PR, James B, Koh MY, Lemos R, Kingston J, Aleshin A, Bankston LA, Miller CP, Cho EJ, Edupuganti R, Devkota A, Stancu G, Liddington RC, Dalby K, Powis G (2016). Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1α Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target. Cancer Res, 76(14), 4259-4269.
  4. Koh MY, Gagea M, Sargis T, Lemos R Jr, Grandjean G, Charbono A, Bekiaris V, Sedy J, Kiriakova G, Liu X, Roberts LR, Ware C, Powis G (2016). A new HIF-1α/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice. Hepatology, 63(5), 1576-91.
  5. Koh MY, Nguyen V, Lemos R Jr, Darnay BG, Kiriakova G, Abdelmelek M, Ho TH, Karam J, Monzon FA, Jonasch E, Powis G (2014). Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma. Cancer Res, 75(2), 316-29.
  6. Koh MY, Powis G (2012). Passing the baton: the HIF switch. Trends Biochem Sci, 37(9), 364-72.
  7. Koh MY, Lemos R Jr, Liu X, Powis G (2011). The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res, 71(11), 4015-27.
  8. Koh MY, Spivak-Kroizman TR, Powis G (2009). HIF-1alpha and cancer therapy. Recent Results Cancer Res, 180, 15-34.
  9. Koh MY, Spivak-Kroizman TR, Powis G (2009). Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clin Cancer Res, 15(19), 5945-6.
  10. Koh MY, Powis G (2009). HAF : the new player in oxygen-independent HIF-1alpha degradation. Cell Cycle, 8(9), 1359-66.
  11. Koh MY, Darnay BG, Powis G (2008). Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol Cell Biol, 28(23), 7081-95.
  12. Baker AF, Koh MY, Williams RR, James B, Wang H, Tate WR, Gallegos A, Von Hoff DD, Han H, Powis G (2008). Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas, 36(2), 178-86.
  13. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, Powis G (2008). Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther, 7(1), 90-100.
  14. Welsh SJ, Koh MY, Powis G (2006). The hypoxic inducible stress response as a target for cancer drug discovery. Semin Oncol, 33(4), 486-97.
  15. Griffiths GJ, Koh MY, Brunton VG, Cawthorne C, Reeves NA, Greaves M, Tilby MJ, Pearson DG, Ottley CJ, Workman P, Frame MC, Dive C (2004). Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J Biol Chem, 279(44), 46113-21.